10:03 AM EDT, 08/28/2025 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Thursday that the government health insurance board for Quebec, Canada, or RAMQ, has added Fruzaqla to its list of medications eligible for coverage.

The company said RAMQ will reimburse Fruzaqla as a monotherapy for metastatic colorectal cancer patients, who have been previously treated with or are not considered candidates for available standard therapies, under certain criteria.

Takeda said Health Canada granted market authorization for Fruzaqla in September 2024.

Price: 14.96, Change: +0.10, Percent Change: +0.67